Professor Christopher Nutting : Clinical oncology , Medical oncology

Home
Professor Christopher Nutting

Bupa Platinum consultant
Fee assured
Awaiting verification
Open Referral network

Overview

Offers

Face-to-face consultations
Video and telephone consultations
Home chemotherapy

About me

I am a specialist in Radiotherapy and Chemotherapy with a particular interest in reducing side effects of treatment by using highly focussed radiotherapy. I am a leader in treatment of head and neck and thyroid cancers as well as lung cancer.
Our advances in IMRT led to the RMH and ICR winning the prestigious 2013 Quality In Care In Oncology Awards for improving the quality of life for people living with cancer.

Areas of interest

Head and neck cancer; mouth cancer, throat cancer, tonsil cancer, neck cancer, skin cancer, Thyroid Cancer; Thyroid nodules, radioiodine treatment, Lung cancer; Cyberknife; Complex radiotherapy techniques; Intensity Modulated Radiotherapy; Chemotherapy; Clinical trials; Second opinion, radiotherapy side effects,

Medical secretaries

Elizabeth Nartley
The Harley Street Clinic 16 Devonshire Street LONDON W1G 7AE
020 7126 7077
medicalPA@chrisnutting-oncology.co.uk

Sylvia Young
Head and Neck Unit Royal Marsden Hospital Fulham Road LONDON SW3 6JJ
020 7808 2586
medsecchelsea.nutting@rmh.nhs.uk

About me

Current NHS consultant posts held

Royal Marsden Hospital, Chelsea and Sutton

Research interests

I firmly believe that the future of improving outcomes in cancer treatment is through well-designed clinical research.

In collaboration with the Institute of Cancer Research (ICR), I led my team at the Royal Marsden Hospital in developing and refining Intensity-Modulated Radiotherapy (IMRT) which reduces side-effects of radiotherapy treatment by avoiding healthy tissue around the tumour site.

Personal interests

I enjoy running and other sports and spending time with my family

Awards received

Silver Clinical Excellence Award by the NHS in 2015

Quality In Care In Oncology Award for improving the quality of life for people living with cancer, 2013 (team award)

Faculty Member, American Society of Therapeutic Radiation Oncology 2011 and 2012

British Institute of Radiology Mackenzie Davidson Memorial Medal and Lecture 2010

Royal College of Radiologists/IPEM Cochrane-Shanks-Jalill Visiting Professorship Cluj-Napocou, Romania, 2010

Publications

I have written over 150 scientific papers cited in the medical literature. There are the top 5:

Papers on IMRT implementation, culminating in the PARSPORT trial

1. Mehanna H, et al: Epidemiology, presentation, and prevention. BMJ. 2010 Sep 20;341:
Prof Nutting commissioned to lead on a BMJ head and neck cancer review.
2. Clark CH, et al; PARSPORT Trial Management Group. Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol. 2009 Oct;93(1):102-8.
This paper describes a National dosimetry audit for the PARPORT trial. The first time that National QA had been performed for a head and neck IMRT trial in the World
3. Guerrero Urbano MT, et al, PARSPORT Trial Management Group. Target volume definition for head nd neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin Oncol (R Coll Radiol). 2007;19:604-13.
This key publication details the comprehensive target volume definition guidelines for parotid sparing IMRT for the PARSPORT trial. No similar multi-centre National consensus has been published in the literature
4. Nutting CM, et al on behalf of the PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and Neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011 Jan 12.
This was the first reported results of a randomised controlled trial of parotid sparing IMRT demonstrating improvements in patient reported xerostomia, increased saliva production and improvements in global quality of life. This trial is the only RCT in squamous cell carcinoma of the head and neck and has contributed to IMRT becoming the standard of care around the World
5. Miles, E.A., et al., The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol, 2005. 77(3): p. 241-6.
This paper described the impact of introducing IMRT into clinical practice. It was used by the National Cancer Action Team to calculate the impact and cost of a National IMRT implementation after the publication of the PARSPORT trial

Courses offered to GPs

I participate in Local, National and International lectures to general practitioners and specialists around the world
I am currently involved in the installation of one of Britainâ€™s first MR Linac machines at RMH. This offers to revolutionise cancer treatment by combining a scanner to precisely locate the tumour and an accelerator to accurately deliver radiation at the same time.

About my work

My outcomes

My qualifications & training

Qualifications

MBBS University of London 1992
MD University of London 2000
PhD University of London 2012
Fellow Royal College of Physicians RCP 1995
Fellow Royal College of Radiologists RCR 1998

GMC registration

Reference number 3616743

Details of entry to specialist register

Clinical Oncology , 2000

My private practice

Practice hours

Practice
Day
Hours
Appt Bookings

19a Cavendish SquareLondonW1G 0LP
Wednesday
14:00 - 18:00
020 7808 2586

Harley Street Clinic, W1G 8BJ
Friday
09:30 - 13:00
020 7299 0093

The Royal Marsden Hospital Fulham Road LONDON...
Monday
14:00 - 18:00
020 7808 2586

The Royal Marsden Hospital Fulham Road LONDON...
Wednesday
14:00 - 18:00
020 7808 2586

Post treatment communication

Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.

In the event of an urgent query following treatment, Bupa members should use the following contact details

0207 352 8171 Royal Marsden Hospital

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)

The Royal Marsden Hospital (1-5) Cromwell Hospital (1-5)
20365
Follow-up out-patient consultation - remote - (5-50)
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)

The Royal Marsden Hospital (5-50)
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)
X0005
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-56 days - (1-5)

The Royal Marsden Hospital (1-5)
X0007
Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)

The Royal Marsden Hospital (1-5)
20355
Initial out-patient consultation - remote - (1-5)
Show All (7 )...

Report this page Print page

Finder

Note: